Evidence for Efficacy of Antidepressants for Pain Is Limited

THURSDAY, Feb. 2, 2023 (HealthDay News) -- Evidence for the efficacy of antidepressants for pain is limited and often inconclusive, according to research published online Feb. 1 in The BMJ.
Giovanni E. Ferreira, Ph.D., from the University of Sydney, and colleagues conducted an overview of systematic reviews comparing any antidepressant with placebo for any pain condition among adults to examine the efficacy, safety, and tolerability of antidepressants for pain. Data were included from 26 reviews (156 unique trials and >25,000 participants). These reviews reported on the efficacy of eight antidepressant classes and covered 22 pain conditions (42 comparisons).
The researchers found that none of the reviews provided high-certainty evidence for the efficacy of antidepressants for pain for any condition. Antidepressants were found to be efficacious in 11 comparisons (nine conditions), including four with moderate-certainty evidence: serotonin-norepinephrine reuptake inhibitors for back pain, postoperative pain, and neuropathic pain (mean difference, −5.3, −7.3, −6.8, respectively) and fibromyalgia (risk ratio, 1.4). In the remaining comparisons, antidepressants were not efficacious (five comparisons) or the evidence was inconclusive (26 comparisons).
"Ferreira and colleagues' overview adds to mounting evidence challenging the use of medicines for pain. In consequence, a real opportunity is emerging to focus more on what living with pain means for individuals and to change how we think about pain," write the authors of an accompanying editorial.
Several authors disclosed financial ties to the biopharmaceutical and medical technology industries.
Related Posts
Los flotadores de cuello para las piscinas son un peligro para los bebés, advierte la FDA
MIÉRCOLES, 29 de junio de 2022 (HealthDay News) -- Los flotadores de cuello...
FDA Approves New Two-Drug Combo Medicine for Asthma
THURSDAY, Jan. 12, 2023 (HealthDay News) -- Adults with asthma now have a new...
Health Highlights: Sept. 3, 2021
Here are some of HealthDay's top stories for Friday, Sept. 3:Experts push back...
Un nuevo medicamento para el Alzheimer se muestra promisorio en un ensayo clínico en fase 3
MIÉRCOLES, 28 de septiembre de 2022 (HealthDay) -- Eisai, una compañía...